Skip to main content
SpringerLink
Log in
Book cover

Controversies in the Management of Gynecological Cancers pp 145–153Cite as

Does Intraperitoneal Therapy for Ovarian Cancer Have a Future?

  • Chapter
  • First Online:

  • 1009 Accesses

Abstract

Ovarian cancer has a unique pattern of spread, with the majority of disease limited to the peritoneal cavity. Intraperitoneal (IP) delivery of chemotherapeutic agents allows for a higher local concentration of drug for a more prolonged period of time at the major site of disease, providing a rationale for its use in ovarian cancer, although limited by poor penetration of tumor implants. This approach is supported by multiple clinical trials demonstrating improved outcomes for ovarian cancer patients but with uncertainty regarding the optimal selection and scheduling of specific agents. Additional challenges to the adoption of IP therapy include the requirement for initial optimal cytoreductive surgery, experience with catheter placement, staff expertise, and the management of treatment-related toxicity. Nonetheless, the improved survival justifies consideration of IP therapy in appropriate patients. Multiple approaches to decrease toxicity, improve tolerability, and indentify key treatment components are currently being evaluated.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2012;56:106.

    Article  Google Scholar 

  2. du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16 suppl 8:viii7–12.

    PubMed  Google Scholar 

  3. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;9(351):2519–29.

    Article  Google Scholar 

  4. Thigpen T. The if and when of surgical debulking for ovarian carcinoma. N Engl J Med. 2004;351:2544–6.

    Article  CAS  PubMed  Google Scholar 

  5. Fujiwara K, Armstrong DK, Morgan M, Markman M. Principal and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007;17:1–20.

    Article  CAS  PubMed  Google Scholar 

  6. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival impact of maximum cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: a meta-analysis of 6,885 patients. J Clin Oncol. 2002;20:1248–59.

    Article  PubMed  Google Scholar 

  7. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;(8):CD007565. doi:10.1002/14651858.CD007565.pub2.

  8. Weisenberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA. 1955;159:1704–7.

    Google Scholar 

  9. Speyer JL, Collins JM, Dedrick RL, et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 1980;40:567–72.

    CAS  PubMed  Google Scholar 

  10. Markman M, Cleary S, Lucas WE, Howell SB. Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. J Clin Oncol. 1985;3:925–31.

    CAS  PubMed  Google Scholar 

  11. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89:480–7.

    Article  CAS  PubMed  Google Scholar 

  12. Grantab RH, Tannock IF. Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib. BMC Cancer. 2012;12:214.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Jandial DD, Messer K, Farshchi-Heydari S, Pu M, Howell SB. Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model. Gynecol Oncol. 2009;115:362–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583–92.

    Article  CAS  PubMed  Google Scholar 

  15. Markman M. Intraperitoneal chemotherapy. Semin Oncol. 1991;18:248–54.

    CAS  PubMed  Google Scholar 

  16. Alberts DS, Liu PY, Hannigan EF, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–5.

    Article  CAS  PubMed  Google Scholar 

  17. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.

    Article  CAS  PubMed  Google Scholar 

  18. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–7.

    CAS  PubMed  Google Scholar 

  19. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.

    Article  CAS  PubMed  Google Scholar 

  20. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;(11):CD005340.

    Google Scholar 

  21. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage iii ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003;21:3194–200.

    Article  CAS  PubMed  Google Scholar 

  22. Ozols RF, Bookman MA, Young RC. Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med. 2006;354:1641–3.

    Article  CAS  PubMed  Google Scholar 

  23. Gore M, du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol. 2006;24:4528–30.

    Article  PubMed  Google Scholar 

  24. Armstrong DK, Brady MF. Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. J Clin Oncol. 2006;24:4531–3.

    Article  PubMed  Google Scholar 

  25. Wenzel L, Huang HQ, Armstrong DK, Walker JL, Cella D. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:437–43.

    Article  CAS  PubMed  Google Scholar 

  26. Helm CW. Ports and complications for intraperitoneal chemotherapy delivery. BJOG. 2012;119:150–9.

    Article  CAS  PubMed  Google Scholar 

  27. Guile MW, Horne AL, Thompson SD, Gardner GJ, Giuntoli RL, Armstrong DK, Bristow RE. Intraperitoneal chemotherapy for stage III ovarian cancer using the Gynecologic Oncology Group protocol 172 intraperitoneal regimen: effect of supportive care using aprepitant and pegfilgrastim on treatment completion rate. Clin Ovarian Cancer. 2008;1:68–71.

    Article  CAS  Google Scholar 

  28. Tewari D, Java J, et al. Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: An analysis of a Gynecologic Oncology Group ancillary data study. Gynecol Oncol 2013;130:e1–e169.

    Google Scholar 

  29. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699–708.

    Article  CAS  PubMed  Google Scholar 

  30. Howell SB. Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer. Int J Gynecol Cancer. 2008;18 Suppl 1:20–5.

    Article  PubMed  Google Scholar 

  31. Los G, Verdegaal EM, Mutsaers PH, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159–65.

    Article  CAS  PubMed  Google Scholar 

  32. Markman M, Reichman B, Hakes T, Rubin S, Lewis Jr JL, Jones W, et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol Oncol. 1993;50:100–4.

    Article  CAS  PubMed  Google Scholar 

  33. Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin—a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol. 2005;99:591–6.

    Article  CAS  PubMed  Google Scholar 

  34. Morgan MA, Sill MW, Fujiwara K, et al. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;121:264–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331–8.

    Article  CAS  PubMed  Google Scholar 

  36. Seamon LG, Richardson DL, Copeland LJ. Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer. Clin Obstet Gynecol. 2012;55:131–55.

    Article  PubMed  Google Scholar 

  37. Bristow RE, Zahurak ML, Diaz-Montes TP, Giuntoli RL, Armstrong DK. Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. Gynecol Oncol. 2009;115:334–8.

    Article  PubMed  Google Scholar 

  38. Havrilesky LJ, Secord AA, Darcy KM, Armstrong DK, Kulasingam S. Cost-effectiveness analysis of intraperitoneal versus intravenous chemotherapy for women with optimally-resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2008;26:4144–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Bristow RE, Santillan A, Salani R, et al. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for stage III ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol. 2007;106:476–81.

    Article  CAS  PubMed  Google Scholar 

  40. Bookman MA, Brady MF, et al. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: a Phase III trial of the Gynecologic Cancer InterGroup (GCIG). J Clin Oncol 2009;27:1419–25.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology, Johns Hopkins Kimmel Cancer Center, The Johns Hopkins Hospital, 1650 Orleans Street, Room 190, Baltimore, 21287, MD, USA

    Deborah K. Armstrong MD

  2. Division of Hematology-Oncology, University of Arizona Cancer Center, 1515 N Campbell Avenue, Room 1903, Tucson, 85724-5024, AZ, USA

    Michael A. Bookman MD

Authors
  1. Deborah K. Armstrong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael A. Bookman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah K. Armstrong MD .

Editor information

Editors and Affiliations

  1. UCL Cancer Institute, University College London, London, United Kingdom

    Jonathan A. Ledermann

  2. Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands

    Carien L. Creutzberg

  3. Royal Women’s Hospital, The University of Melbourne, Melbourne, Australia

    Michael A. Quinn

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Armstrong, D.K., Bookman, M.A. (2014). Does Intraperitoneal Therapy for Ovarian Cancer Have a Future?. In: Ledermann, J., Creutzberg, C., Quinn, M. (eds) Controversies in the Management of Gynecological Cancers. Springer, London. https://doi.org/10.1007/978-0-85729-910-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-910-9_14

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-909-3

  • Online ISBN: 978-0-85729-910-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation